• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Steven J. Skates, PhD


  • Skates SJ.A statistical challenge: developing tests for biomarker utility specific to the intended use.Journal of the National Cancer Institute. 2014 Apr;106(4):dju076.
  • Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES.Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.J Proteome Res. 2013 Dec 6;12(12):5383-94.
  • Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum.Dis Markers. 2013;35(2):119-27.
  • Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC.A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.Cancer. 2013 Oct 1;119(19):3454-61.
  • Abbatiello SE, Mani DR, Schilling B, Maclean B, Zimmerman LJ, Feng X, Cusack MP, Sedransk N, Hall SC, Addona T, Allen S, Dodder NG, Ghosh M, Held JM, Hedrick V, Inerowicz HD, Jackson A, Keshishian H, Kim JW, Lyssand JS, Riley CP, Rudnick P, Sadowski P, Shaddox K, Smith D, Tomazela D, Wahlander A, Waldemarson S, Whitwell CA, You J, Zhang S, Kinsinger CR, Mesri M, Rodriguez H, Borchers CH, Buck C, Fisher SJ, Gibson BW, Liebler D, Maccoss M, Neubert TA, Paulovich A, Regnier F, Skates SJ, Tempst P, Wang M, Carr SA.Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS).Mol Cell Proteomics. 2013 Sep;12(9):2623-39.
  • Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD.Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.Int J Cancer. 2013 May 1;132(9):2127-33.
  • Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ.Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.J Clin Oncol. 2013 Jan 1;31(1):49-57.
  • Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J, Skates S, Parmar M, Seif MW, Amso NN, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Campbell S, Fallowfield L, Jacobs I, Menon U.Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials.Trials. 2011;12:61.
  • Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-Which is best?.Lung Cancer. 2011 Mar 11.
  • Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.Cancer Prev Res (Phila Pa). 2011 Mar;4(3):365-74.
  • Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD, .A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer.Cancer Prev Res (Phila Pa). 2011 Mar;4(3):375-383.
  • Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif MW, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Skates SJ, Fallowfield L, Parmar M, Campbell S, Menon U.Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.Lancet Oncol. 2011 Jan;12(1):38-48.
  • Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW.Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2238-46.
  • Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ.Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.Am J Obstet Gynecol. 2010 Sep;203(3):228.e1-6.
  • Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip R, Ransohoff DF, Skates SJ, Regnier FE, Anderson NL, Mansfield E, .Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.Clin Chem. 2010 Feb;56(2):237-43. Review.
  • Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, Alterman MA, Levin JD, Roscoe D, Reilly E, Callaghan J, Kelm K, Brown D, Philip R, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Ransohoff DF, Mansfield E, Anderson NL.Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.Clin Chem. 2010 Feb;56(2):165-71.
  • Hulick P, Zimmer M, Margulis V, Skates S, Hamel M, Dahl DM, Michaelson DM, Libermann T, Signoretti S, Carney W, Wood C, Iliopoulos O.Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity.Clin. Proteomics.;5(1):37-45.
  • Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, Rodriguez H, Rudnick PA, Smith D, Tabb DL, Tegeler TJ, Variyath AM, Vega-Montoto LJ, Wahlander A, Waldemarson S, Wang M, Whiteaker JR, Zhao L, Anderson NL, Fisher SJ, Liebler DC, Paulovich AG, Regnier FE, Tempst P, Carr SA.Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.Nat Biotechnol. 2009 Jul;27(7):633-41.
  • Menon U,Gentry-Maharaj A,Hallett R,Ryan A,Burnell M,Sharma A,Lewis S,Davies S,Philpott S,Lopes A,Godfrey K,Oram D,Herod J,Williamson K,Seif MW,Scott I,Mould T,Woolas R,Murdoch J,Dobbs S,Amso NN,Leeson S,Cruickshank D,McGuire A,Campbell S,Fallowfield L,Singh N,Dawnay A,Skates SJ,Parmar M,Jacobs I.Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).Lancet Oncol. 2009 Apr;10(4):327-40.
  • Moore RG,McMeekin DS,Brown AK,DiSilvestro P,Miller MC,Allard WJ,Gajewski W,Kurman R,Bast RC Jr,Skates SJ.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol. 2009 Jan;112(1):40-6.
  • Drapkin R, Clauss A, Skates S.Urokinase-type plasminogen activator receptor: a beacon of malignancy?.Clin Cancer Res. 2008 Sep 15;14(18):5643-5.
  • Creaney J,Yeoman D,Demelker Y,Segal A,Musk AW,Skates SJ,Robinson BW.Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.J Thorac Oncol. 2008 Aug;3(8):851-7.
  • Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S.A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a gynecologic oncology group study.Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604.
  • Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol Oncol. 2008 Feb;108(2):402-8.
  • Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr.Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.Gynecol Oncol. 2007 Dec;107(3):526-31.
  • Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A.Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.Gynecol Oncol. 2007 Oct;107(1):58-65.
  • Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW.Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.Chest. 2007 Oct;132(4):1239-46.
  • Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, Domchek SM, Tomlinson G, Skates SJ, Gatsonis C.Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.Radiology. 2007 Aug;244(2):381-8.
  • Creaney J, Yeoman D, Naumoff L, Hof M, Segal A, Musk WA, De Klerk N, Horick N, Skates SJ, Robinson BW.Soluble mesothelin in effusions - a useful tool for the diagnosis of malignant mesothelioma.Thorax. 2007 Jul;62(7):569-76.
  • Skates SJ, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, Sluss P, Cramer DW.Pooling of case specimens to create standard serum sets for screening cancer biomarkers.Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41.
  • Jacobs IJ, Mackay J, Menon U, Skates SJ, Rosenthal AN, Fraser L.Familial ovarian screening--effective or ineffective?.Br J Cancer. 2006 Oct 23;95(8):1124; author reply 1126-7.
  • Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, Skates S.Evaluating markers for the early detection of cancer: overview of study designs and methods.Clin Trials. 2006;3(1):43-56. Review.
  • Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW.Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.Clin Cancer Res. 2006 Jan 15;12(2):432-41.
  • Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.New tumor markers: CA125 and beyond.Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81.
  • Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC, Oram D, Jacobs IJ.Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.J Clin Oncol. 2005 Nov 1;23(31):7919-26.
  • Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW.Blood and urine markers for ovarian cancer: a comprehensive review.Dis Markers. 2004;20(2):53-70.
  • Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM,.Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with mllerian malignancies.Gynecol Oncol. 2004 Jun;93(3):702-7.
  • Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC.Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.Clin Cancer Res. 2004 May 15;10(10):3474-8.
  • Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF, Goodman A, Seiden MV.Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.Gynecol Oncol. 2004 Apr;93(1):98-106.
  • Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC.Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.Clin Cancer Res. 2003 Oct 15;9(13):4782-91.
  • Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC.Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.Clin Cancer Res. 2003 Aug 1;9(8):2904-11.
  • Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L.Progress in the management of gynecologic cancer: consensus summary statement.J Clin Oncol. 2003 May 15;21(10 Suppl):129-32.
  • O'Regan A, Fleming C, Seidman JD, Wallach RC, Mok SC, Skates SJ, Berkowitz RS, Cramer DW.Osteopontin as a biomarker for ovarian cancer.JAMA. 2002 Jun 26;287:3208-3210.
  • Kim JH, Skates SJ, Uede T, Wong Kk KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC.Osteopontin as a potential diagnostic biomarker for ovarian cancer.JAMA. 2002 Apr 3;287(13):1671-9.
  • Skates SJ.Screening for ovarian cancer-risk, education, worry: path to appropriate use?.Gynecol Oncol. 2002 Apr;85(1):1-2.
  • Parmigiani G, Skates S, Zelen M.Modeling and optimization in early detection programs with a single exam.Biometrics. 2002 Mar;58(1):30-6.
  • Bast RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G.Early detection of ovarian cancer: promise and reality.Cancer Treat Res. 2002;107:61-97.
  • Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW.Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.J Natl Cancer Inst. 2001 Oct 3;93(19):1458-64.
  • Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ.Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin.Ann Intern Med. 2001 Sep 18;135(6):393-400.
  • Skates SJ, Pauler DK, Jacobs IJ.Calculation from Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers.Journal of American Statistical Association. 2001 Jun 01;96:429-439.
  • Skates SJ, Pauler DK, Jacobs IJ.Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers.Survey Methodol. 2001 Jun;96(454):429-439.
  • Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ.Factors influencing serum CA125II levels in healthy postmenopausal women.Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93.
  • Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE.Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.Arch Intern Med. 2000 Jun 12;160(11):1612-7.
  • Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ.Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.BJOG. 2000 Feb;107(2):165-9.
  • Menon U, Talaat A, Jeyarajah AR, Rosenthal AN, MacDonald ND, Skates SJ, Sibley K, Oram DH, Jacobs IJ.Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.Br J Cancer. 1999 Jul;80(10):1644-7.
  • Jeyarajah AR, Ind TE, Skates S, Oram DH, Jacobs IJ.Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.Cancer. 1999 May 1;85(9):2068-72.
  • Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH.Screening for ovarian cancer: a pilot randomised controlled trial.Lancet. 1999 Apr 10;353(9160):1207-10.
  • Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA.The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.Br J Urol. 1998 Aug;82(2):231-6.
  • Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE.Acetaminophen and other risk factors for excessive warfarin anticoagulation.JAMA. 1998 Mar 4;279(9):657-62.
  • Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL.Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease.Ann Intern Med. 1997 Jun 1;126(11):866-73.
  • Hylek EM, Skates SJ, Sheehan MA, Singer DE.An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.N Engl J Med. 1996 Aug 22;335(8):540-6.
  • Skates SJ, Xu FJ, Yu YH, Sjvall K, Einhorn N, Chang Y, Bast RC, Knapp RC.Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.Cancer. 1995 Nov 15;76(10 Suppl):2004-10.
  • Atlas SJ, Singer DE, Skates SJ.Changing blood use in the AIDS era: the case of elective hip surgery.Transfusion. 1994 May;34(5):386-91.
  • Urie MM, Fullerton B, Tatsuzaki H, Birnbaum S, Suit HD, Convery K, Skates S, Goitein M.A dose response analysis of injury to cranial nerves and/or nuclei following proton beam radiation therapy.Int J Radiat Oncol Biol Phys. 1992;23(1):27-39.
  • Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR.The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass.JAMA. 1991 Mar 6;265(9):1133-8.
  • Skates SJ, Singer DE.Quantifying the potential benefit of CA 125 screening for ovarian cancer.J Clin Epidemiol. 1991;44(4-5):365-80.
  • Eagle KA, Mulley AG, Skates SJ, Reder VA, Nicholson BW, Sexton JO, Barnett GO, Thibault GE.Length of stay in the intensive care unit. Effects of practice guidelines and feedback.JAMA. 1990 Aug 22-29;264(8):992-7.
  • Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ.Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.Cancer Res. 1989 Dec 15;49(24 Pt 1):7147-52.
  • Suit HD, Baumann M, Skates S, Convery K.Clinical interest in determinations of cellular radiation sensitivity.Int J Radiat Biol. 1989 Nov;56(5):725-37.
  • Lauk S, Skates S, Goodman M, Suit HD.A morphometric study of the vascularity of oral squamous cell carcinomas and its relation to outcome of radiation therapy.Eur J Cancer Clin Oncol. 1989 Oct;25(10):1431-40.
  • Lauk S, Zietman A, Skates S, Fabian R, Suit HD.Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice.Cancer Res. 1989 Aug 15;49(16):4557-61.
  • Okunieff P, Rummeny E, Vaupel P, Skates S, Willett C, Neuringer LJ, Suit HD.Effects of pentobarbital anesthesia on the energy metabolism of murine tumors studied by in vivo 31P nuclear magnetic resonance spectroscopy.Radiat Res. 1988 Aug;115(2):361-72.
  • Willett CG, Stracher MA, Linggood RM, Miketic LM, Leong JC, Skates SJ, Kushner DC, Jacobson JO.Three-dimensional volumetric assessment of response to treatment: stage I and II diffuse large cell lymphoma of the mediastinum.Radiother Oncol. 1988 Jul;12(3):193-8.
  • Willett CG, Linggood RM, Leong JC, Miketic LM, Stracher MA, Skates SJ, Kushner DC.Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment.J Clin Oncol. 1988 May;6(5):819-24.
  • Willett CG, Tepper JE, Skates SJ, Wood WC, Orlow EC, Duttenhaver JR.Adjuvant postoperative radiation therapy for colonic carcinoma.Ann Surg. 1987 Dec;206(6):694-8.